{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:23:54Z","timestamp":1793820234817,"version":"4.6.1"},"reference-count":222,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s12325-022-02281-4","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T15:02:55Z","timestamp":1662390175000},"page":"4910-4960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19"],"prefix":"10.1007","volume":"39","author":[{"given":"Thomas","family":"Bieber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Haladyj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Deberdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"issue":"9","key":"2281_CR1","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298\u2013307. https:\/\/doi.org\/10.4049\/jimmunol.0902819.","journal-title":"J Immunol"},{"issue":"1","key":"2281_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. https:\/\/doi.org\/10.1186\/s13075-019-1964-1.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2281_CR3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","volume":"76","author":"W Damsky","year":"2017","unstructured":"Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736\u201344. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.005.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2281_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25\u201336. https:\/\/doi.org\/10.1038\/nrrheum.2015.167.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"2281_CR5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019;58(6):953\u201362. https:\/\/doi.org\/10.1093\/rheumatology\/key339.","journal-title":"Rheumatology (Oxford)"},{"key":"2281_CR6","unstructured":"Eli Lilly. Olumiant. Baricitinib. Summary of Product Characteristics. 29 November 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-epar-product-information_en.pdf. Accessed Apr 07, 2022."},{"key":"2281_CR7","unstructured":"US Food and Drug Administration. FDA approves first systemic treatment for alopecia areata. June 13, 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-systemic-treatment-alopecia-areata. Accessed Jun 30, 2022."},{"key":"2281_CR8","unstructured":"US Food and Drug Administration. Frequently asked questions on Olumiant (baricitinib) for the treatment of COVID-19. https:\/\/www.fda.gov\/media\/143825\/download. Accessed May 25, 2022"},{"issue":"8","key":"2281_CR9","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012697","volume":"12","author":"J Stebbing","year":"2020","unstructured":"Stebbing J, Krishnan V, de Bono S, et al. Sacco Baricitinib Study Group. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020;12(8): e12697. https:\/\/doi.org\/10.15252\/emmm.202012697.","journal-title":"EMBO Mol Med"},{"issue":"3Suppl","key":"2281_CR10","doi-asserted-by":"publisher","first-page":"AB108","DOI":"10.1016\/j.jaad.2021.06.450","volume":"85","author":"A Paller","year":"2021","unstructured":"Paller A, Chu C-Y, Yang C-Y, et al. Baricitinib for the treatment of pediatric patients with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021;85(3Suppl):AB108. https:\/\/doi.org\/10.1016\/j.jaad.2021.06.450.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2281_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1186\/s13063-021-05651-5","volume":"22","author":"AV Ramanan","year":"2021","unstructured":"Ramanan AV, Guly CM, Keller SY, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase\u00a03 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. https:\/\/doi.org\/10.1186\/s13063-021-05651-5.","journal-title":"Trials"},{"issue":"7","key":"2281_CR12","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","volume":"128","author":"GA Montealegre Sanchez","year":"2018","unstructured":"Montealegre Sanchez GA, Reinhardt A, Ramsey S, et al. JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128(7):3041\u201352. https:\/\/doi.org\/10.1172\/JCI98814.","journal-title":"J Clin Invest"},{"issue":"10","key":"2281_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","volume":"383","author":"A Vanderver","year":"2020","unstructured":"Vanderver A, Adang L, Gavazzi F, et al. Janus kinase inhibition in the Aicardi-Gouti\u00e8res syndrome. N Engl J Med. 2020;383(10):986\u20139. https:\/\/doi.org\/10.1056\/NEJMc2001362.","journal-title":"N Engl J Med"},{"issue":"10143","key":"2281_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase\u00a02 trial. Lancet. 2018;392(10143):222\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(18)31363-1.","journal-title":"Lancet"},{"key":"2281_CR15","doi-asserted-by":"crossref","unstructured":"Morand EF, Tanaka Y, Furie R, et al. Efficacy and safety of baricitinib in patients with systemic lupus erythematosus: results from two randomised, double-blind, placebo-controlled, parallel-group, phase\u00a03 studies (abstract 1968). Presented at EULAR 2022.","DOI":"10.1136\/annrheumdis-2022-eular.1968"},{"issue":"6","key":"2281_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","volume":"174","author":"KA Papp","year":"2016","unstructured":"Papp KA, Menter MA, Raman M, et al. A randomized phase\u00a02b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266\u201376. https:\/\/doi.org\/10.1111\/bjd.14403.","journal-title":"Br J Dermatol"},{"issue":"11","key":"2281_CR17","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","volume":"33","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Brosius FC 3rd, Adler SG, et al. JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a phase\u00a02 randomized controlled clinical trial. Nephrol Dial Transplant. 2018;33(11):1950\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfx377.","journal-title":"Nephrol Dial Transplant"},{"key":"2281_CR18","unstructured":"US Food and Drug Administration. CFR\u2013Code of Federal Regulations Title 21. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/cfrsearch.cfm?fr=312.32. Accessed Apr 29, 2022."},{"key":"2281_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2022.2039122","volume":"10","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R. Recent issues in JAK inhibitor safety: perspective for the clinician. Expert Rev Clin Immunol. 2022;10:1\u201313. https:\/\/doi.org\/10.1080\/1744666X.2022.2039122.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2281_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/annrheumdis-2013-204223","volume":"73","author":"M Dougados","year":"2014","unstructured":"Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204223.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2281_CR21","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/art.27425","volume":"62","author":"E Myasoedova","year":"2010","unstructured":"Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955\u20132007. Arthritis Rheum. 2010;62(6):1576\u201382. https:\/\/doi.org\/10.1002\/art.27425.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2281_CR22","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/09546634.2020.1866741","volume":"32","author":"M De Bruin-Weller","year":"2021","unstructured":"De Bruin-Weller M, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021;32(2):164\u201373. https:\/\/doi.org\/10.1080\/09546634.2020.1866741.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"2281_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/all.13085","volume":"72","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Andersen YM, Gislason GH, Skov L, Thyssen JP. Prevalence of comorbidity and associated risk factors in adults with atopic dermatitis. Allergy. 2017;72(5):783\u201391. https:\/\/doi.org\/10.1111\/all.13085.","journal-title":"Allergy"},{"issue":"6","key":"2281_CR24","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/jdv.16078","volume":"34","author":"A Heratizadeh","year":"2020","unstructured":"Heratizadeh A, Haufe E, St\u00f6lzl D, et al. TREATgermany Study Group. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol. 2020;34(6):1263\u201372. https:\/\/doi.org\/10.1111\/jdv.16078.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2281_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s13555-021-00491-2","volume":"11","author":"A Egeberg","year":"2021","unstructured":"Egeberg A, Thyssen JP, Wu JJ, Pierce E, Terres JAR. Treatment patterns in Danish patients with atopic dermatitis before and after hospital referral. Dermatol Ther (Heidelb). 2021;11(2):499\u2013512. https:\/\/doi.org\/10.1007\/s13555-021-00491-2.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"2281_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2013.3049","volume":"149","author":"KP Huang","year":"2013","unstructured":"Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149(7):789\u201394. https:\/\/doi.org\/10.1001\/jamadermatol.2013.3049.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2281_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/ced.14507","volume":"46","author":"A Egeberg","year":"2021","unstructured":"Egeberg A, Anderson S, Edson-Heredia E, Burge R. Comorbidities of alopecia areata: a population-based cohort study. Clin Exp Dermatol. 2021;46(4):651\u20136. https:\/\/doi.org\/10.1111\/ced.14507.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"2281_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053137","volume":"12","author":"YMF Andersen","year":"2022","unstructured":"Andersen YMF, Nymand L, DeLozier AM, Burge R, Edson-Heredia E, Egeberg A. Patient characteristics and disease burden of alopecia areata in the Danish Skin Cohort. BMJ Open. 2022;12(2): e053137. https:\/\/doi.org\/10.1136\/bmjopen-2021-053137.","journal-title":"BMJ Open"},{"issue":"4","key":"2281_CR29","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","volume":"134","author":"SA Mirzoyev","year":"2014","unstructured":"Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990\u20132009. J Invest Dermatol. 2014;134(4):1141\u20132. https:\/\/doi.org\/10.1038\/jid.2013.464.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2281_CR30","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/jcm10050998","volume":"10","author":"I Gergianaki","year":"2021","unstructured":"Gergianaki I, Garantziotis P, Adamichou C, et al. High comorbidity burden in patients with SLE: data from the community-based lupus registry of crete. J Clin Med. 2021;10(5):998. https:\/\/doi.org\/10.3390\/jcm10050998.","journal-title":"J Clin Med"},{"issue":"10","key":"2281_CR31","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3899\/jrheum.141112","volume":"42","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian dermatology-rheumatology comorbidity initiative. J Rheumatol. 2015;42(10):1767\u201380. https:\/\/doi.org\/10.3899\/jrheum.141112.","journal-title":"J Rheumatol"},{"issue":"9","key":"2281_CR32","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200726.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2281_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","volume":"137","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Councilors of the International Eczema Council. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18\u201325. https:\/\/doi.org\/10.1016\/j.jid.2016.08.022.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2281_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13671-017-0168-7","volume":"6","author":"YMF Andersen","year":"2017","unstructured":"Andersen YMF, Egeberg A, Skov L, Thyssen JP. Comorbidities of atopic dermatitis: beyond rhinitis and asthma. Curr Dermatol Rep. 2017;6(1):35\u201341. https:\/\/doi.org\/10.1007\/s13671-017-0168-7.","journal-title":"Curr Dermatol Rep"},{"issue":"2","key":"2281_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4168\/aair.2011.3.2.67","volume":"3","author":"T Zheng","year":"2011","unstructured":"Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3(2):67\u201373. https:\/\/doi.org\/10.4168\/aair.2011.3.2.67.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"2","key":"2281_CR36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaci.2012.10.041","volume":"131","author":"P Yaghmaie","year":"2013","unstructured":"Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428\u201333. https:\/\/doi.org\/10.1016\/j.jaci.2012.10.041.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2281_CR37","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","volume":"135","author":"FJ Dalgard","year":"2015","unstructured":"Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984\u201391. https:\/\/doi.org\/10.1038\/jid.2014.530.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2281_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaad.2018.07.013","volume":"80","author":"S Lee","year":"2019","unstructured":"Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(2):466\u201377. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.013.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2281_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1586\/eci.10.98","volume":"7","author":"M McMahon","year":"2011","unstructured":"McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011;7(2):227\u201341. https:\/\/doi.org\/10.1586\/eci.10.98.","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"2281_CR40","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1002\/art.22924","volume":"56","author":"MJ Roman","year":"2007","unstructured":"Roman MJ, Crow MK, Lockshin MD, et al. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2007;56(10):3412\u20139. https:\/\/doi.org\/10.1002\/art.22924.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2281_CR41","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.mayocp.2019.01.044","volume":"94","author":"G Katz","year":"2019","unstructured":"Katz G, Smilowitz NR, Blazer A, Clancy R, Buyon JP, Berger JS. Systemic lupus erythematosus is associated with increased prevalence of atherosclerotic cardiovascular disease in hospitalized patients. Mayo Clin Proc. 2019;94(8):1436\u201343. https:\/\/doi.org\/10.1016\/j.mayocp.2019.01.044.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2281_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.680043","volume":"28","author":"S Shams","year":"2021","unstructured":"Shams S, Martinez JM, Dawson JRD, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol. 2021;28(12): 680043. https:\/\/doi.org\/10.3389\/fphar.2021.680043.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2281_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","volume":"10","author":"E Darwin","year":"2018","unstructured":"Darwin E, Hirt PA, Fertig R, Doliner B, Delcanto G, Jimenez JJ. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichol. 2018;10(2):51\u201360. https:\/\/doi.org\/10.4103\/ijt.ijt_99_17.","journal-title":"Int J Trichol"},{"issue":"6","key":"2281_CR44","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736\u201345. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2281_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kes305.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2281_CR46","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287\u201393. https:\/\/doi.org\/10.1002\/art.10524.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"2281_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.31138\/mjr.31.1.129","volume":"31","author":"K Thomas","year":"2020","unstructured":"Thomas K, Vassilopoulos D. Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol. 2020;31(Suppl 1):129\u201336. https:\/\/doi.org\/10.31138\/mjr.31.1.129.","journal-title":"Mediterr J Rheumatol"},{"key":"2281_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11376","author":"RK Dore","year":"2021","unstructured":"Dore RK, Antonova JN, Burudpakdee C, Chang L, Gorritz M, Genovese MC. The incidence, prevalence, and associated costs of anemia, malignancy, venous thromboembolism, major adverse cardiovascular events, and infections in rheumatoid arthritis patients by treatment history in the United States. ACR Open Rheumatol. 2021. https:\/\/doi.org\/10.1002\/acr2.11376.","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"2281_CR49","doi-asserted-by":"publisher","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","volume":"7","author":"F Marra","year":"2020","unstructured":"Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. https:\/\/doi.org\/10.1093\/ofid\/ofaa005.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2281_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000935","volume":"5","author":"B Mehta","year":"2019","unstructured":"Mehta B, Pedro S, Ozen G, et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019;5(1): e000935. https:\/\/doi.org\/10.1136\/rmdopen-2019-000935.","journal-title":"RMD Open"},{"issue":"6","key":"2281_CR51","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","volume":"19","author":"A Paller","year":"2018","unstructured":"Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19(6):821\u201338. https:\/\/doi.org\/10.1007\/s40257-018-0383-4.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2281_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/DER.0000000000000526","volume":"31","author":"Z Ren","year":"2020","unstructured":"Ren Z, Silverberg JI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections. Dermatitis. 2020;31(2):157\u201364. https:\/\/doi.org\/10.1097\/DER.0000000000000526.","journal-title":"Dermatitis"},{"key":"2281_CR53","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.20887","volume":"186","author":"J Wan","year":"2021","unstructured":"Wan J, Shin DB, Syed MN, Abuabara K, Lemeshow AR, Gelfand JM. Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study. Br J Dermatol. 2022;186(4):664\u201372. https:\/\/doi.org\/10.1111\/bjd.20887.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2281_CR54","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.anai.2017.10.019","volume":"120","author":"S Narla","year":"2018","unstructured":"Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. Ann Allergy Asthma Immunol. 2018;120(1):66-72.e11. https:\/\/doi.org\/10.1016\/j.anai.2017.10.019.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"2281_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045718","volume":"11","author":"M Harries","year":"2021","unstructured":"Harries M, Macbeth AE, Holmes S, et al. Epidemiology, management and the associated burden of mental health illness, atopic and autoimmune conditions, and common infections in alopecia areata: protocol for an observational study series. BMJ Open. 2021;11(11): e045718. https:\/\/doi.org\/10.1136\/bmjopen-2020-045718.","journal-title":"BMJ Open"},{"issue":"1","key":"2281_CR56","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/rheumatology\/keaa478","volume":"60","author":"JM Pego-Reigosa","year":"2021","unstructured":"Pego-Reigosa JM, Nicholson L, Pooley N, et al. The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(1):60\u201372. https:\/\/doi.org\/10.1093\/rheumatology\/keaa478.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2281_CR57","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/acr.23567","volume":"70","author":"K Lauper","year":"2018","unstructured":"Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C. Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res (Hoboken). 2018;70(12):1756\u201363. https:\/\/doi.org\/10.1002\/acr.23567.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"2281_CR58","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.semarthrit.2018.03.005","volume":"48","author":"R Cooksey","year":"2018","unstructured":"Cooksey R, Brophy S, Kennedy J, et al. Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Semin Arthritis Rheum. 2018;48(3):367\u201373. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.005.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2281_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001113","volume":"6","author":"A De Thurah","year":"2020","unstructured":"De Thurah A, Andersen IT, Tinggaard AB, et al. Risk of major adverse cardiovascular events among patients with rheumatoid arthritis after initial CT-based diagnosis and treatment. RMD Open. 2020;6(1):e001113. https:\/\/doi.org\/10.1136\/rmdopen-2019-001113.","journal-title":"RMD Open"},{"issue":"3","key":"2281_CR60","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3899\/jrheum.180726","volume":"47","author":"R Agca","year":"2020","unstructured":"Agca R, Hopman LHGA, Laan KJC, et al. Cardiovascular event risk in rheumatoid arthritis compared with type\u00a02 diabetes: a 15-year longitudinal study. J Rheumatol. 2020;47(3):316\u201324. https:\/\/doi.org\/10.3899\/jrheum.180726.","journal-title":"J Rheumatol"},{"key":"2281_CR61","doi-asserted-by":"publisher","unstructured":"Andersen YMF, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(1):310\u2013312.e3. https:\/\/doi.org\/10.1016\/j.jaci.2016.01.015. Supplementary table E1: https:\/\/www.jacionline.org\/action\/showFullTableHTML?isHtml=true&tableId=tblE1&pii=S0091-6749%2816%2900199-8.","DOI":"10.1016\/j.jaci.2016.01.015"},{"issue":"5","key":"2281_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250216","volume":"16","author":"H Lee","year":"2021","unstructured":"Lee H, Kim YC, Choi JW. Alopecia areata is not a risk factor for heart diseases: a 10-year retrospective cohort study. PLoS\u00a0One. 2021;16(5): e0250216. https:\/\/doi.org\/10.1371\/journal.pone.0250216.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"2281_CR63","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jaad.2016.02.1234","volume":"75","author":"KP Huang","year":"2016","unstructured":"Huang KP, Joyce CJ, Topaz M, Guo Y, Mostaghimi A. Cardiovascular risk in patients with alopecia areata (AA): a propensity-matched retrospective analysis. J Am Acad Dermatol. 2016;75(1):151\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2016.02.1234.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2281_CR64","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/art.40174","volume":"69","author":"M Barbhaiya","year":"2017","unstructured":"Barbhaiya M, Feldman CH, Guan H, et al. Race\/ethnicity and cardiovascular events among patients with systemic lupus erythematosus. Arthritis Rheumatol. 2017;69(9):1823\u201331. https:\/\/doi.org\/10.1002\/art.40174.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2281_CR65","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/acr.23018","volume":"69","author":"JA Avi\u00f1a-Zubieta","year":"2017","unstructured":"Avi\u00f1a-Zubieta JA, To F, Vostretsova K, De Vera M, Sayre EC, Esdaile JM. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res (Hoboken). 2017;69(6):849\u201356. https:\/\/doi.org\/10.1002\/acr.23018.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2281_CR66","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/keaa262","volume":"60","author":"L Li","year":"2021","unstructured":"Li L, Lu N, Avina-Galindo AM, et al. The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study. Rheumatology (Oxford). 2021;60(1):188\u201395. https:\/\/doi.org\/10.1093\/rheumatology\/keaa262.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2281_CR67","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1136\/ard.2011.153536","volume":"70","author":"R Davies","year":"2011","unstructured":"Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. BSRBR Control Centre Consortium, British Society for Rheumatology Biologics Register. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(10):1831\u20134. https:\/\/doi.org\/10.1136\/ard.2011.153536.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2281_CR68","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/acr.22039","volume":"65","author":"SC Kim","year":"2013","unstructured":"Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(10):1600\u20137. https:\/\/doi.org\/10.1002\/acr.22039.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"13","key":"2281_CR69","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/2012.jama.11741","volume":"308","author":"ME Holmqvist","year":"2012","unstructured":"Holmqvist ME, Neovius M, Eriksson J, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization. JAMA. 2012;308(13):1350\u20136. https:\/\/doi.org\/10.1001\/2012.jama.11741.","journal-title":"JAMA"},{"issue":"2","key":"2281_CR70","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/annrheumdis-2016-209315","volume":"76","author":"JK Eriksson","year":"2017","unstructured":"Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017;76(2):364\u201370. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209315.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2281_CR71","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.33322","volume":"64","author":"AK Bacani","year":"2012","unstructured":"Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 2012;64(1):53\u201361. https:\/\/doi.org\/10.1002\/art.33322.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2281_CR72","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1136\/annrheumdis-2012-201669","volume":"72","author":"HK Choi","year":"2013","unstructured":"Choi HK, Rho YH, Zhu Y, Cea-Soriano L, Avina-Zubieta JA, Zhang Y. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis. 2013;72(7):1182\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201669.","journal-title":"Ann Rheum Dis"},{"issue":"39","key":"2281_CR73","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","volume":"39","author":"A Ogdie","year":"2018","unstructured":"Ogdie A, Kay McGill N, Shin DB, et al. Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. Eur Heart J. 2018;39(39):3608\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehx145.","journal-title":"Eur Heart J"},{"issue":"1","key":"2281_CR74","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.thromres.2014.10.012","volume":"135","author":"HR Yusuf","year":"2015","unstructured":"Yusuf HR, Hooper WC, Grosse SD, Parker CS, Boulet SL, Ortel TL. Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees. Thromb Res. 2015;135(1):50\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2014.10.012.","journal-title":"Thromb Res"},{"issue":"4","key":"2281_CR75","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00403-020-02099-6","volume":"313","author":"MS Shaheen","year":"2021","unstructured":"Shaheen MS, Silverberg JI. Association of inflammatory skin diseases with venous thromboembolism in US adults. Arch Dermatol Res. 2021;313(4):281\u20139. https:\/\/doi.org\/10.1007\/s00403-020-02099-6.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"2281_CR76","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s13555-021-00538-4","volume":"11","author":"KJ Meyers","year":"2021","unstructured":"Meyers KJ, Silverberg JI, Rueda MJ, et al. Risk of venous thromboembolism among patients with atopic dermatitis: a cohort study in a US administrative claims database. Dermatol Ther (Heidelb). 2021;11(3):1041\u201352. https:\/\/doi.org\/10.1007\/s13555-021-00538-4.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"2281_CR77","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","volume":"157","author":"MC Schneeweiss","year":"2021","unstructured":"Schneeweiss MC, Kim SC, Wyss R, et al. Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases. JAMA Dermatol. 2021;157(7):805\u201316. https:\/\/doi.org\/10.1001\/jamadermatol.2021.1570.","journal-title":"JAMA Dermatol"},{"issue":"13","key":"2281_CR78","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1177\/0961203317716306","volume":"26","author":"O Ahlehoff","year":"2017","unstructured":"Ahlehoff O, Wu JJ, Rauns\u00f8 J, et al. Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: a Danish nationwide cohort study. Lupus. 2017;26(13):1435\u20139. https:\/\/doi.org\/10.1177\/0961203317716306.","journal-title":"Lupus"},{"issue":"2","key":"2281_CR79","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.semarthrit.2015.05.008","volume":"45","author":"JA Avina-Zubieta","year":"2015","unstructured":"Avina-Zubieta JA, Vostretsova K, De Vera MA, Sayre EC, Choi HK. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study. Semin Arthritis Rheum. 2015;45(2):195\u2013201. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.05.008.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2281_CR80","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3899\/jrheum.071244","volume":"36","author":"J Romero-D\u00edaz","year":"2009","unstructured":"Romero-D\u00edaz J, Garc\u00eda-Sosa I, S\u00e1nchez-Guerrero J. Thrombosis in systemic lupus erythematosus and other autoimmune diseases of recent onset. J Rheumatol. 2009;36(1):68\u201375. https:\/\/doi.org\/10.3899\/jrheum.071244.","journal-title":"J Rheumatol"},{"issue":"1","key":"2281_CR81","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17(1):212. https:\/\/doi.org\/10.1186\/s13075-015-0728-9.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2281_CR82","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40744-017-0064-4","volume":"4","author":"KM Wilton","year":"2017","unstructured":"Wilton KM, Matteson EL. Malignancy incidence, management, and prevention in patients with rheumatoid arthritis. Rheumatol Ther. 2017;4(2):333\u201347. https:\/\/doi.org\/10.1007\/s40744-017-0064-4.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"2281_CR83","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3390\/jcm10030509","volume":"10","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Atzeni F, Balsa A, Gossec L, M\u00fcller-Ladner U, Pope J. The key comorbidities in patients with rheumatoid arthritis: a narrative review. J Clin Med. 2021;10(3):509. https:\/\/doi.org\/10.3390\/jcm10030509.","journal-title":"J Clin Med"},{"issue":"5","key":"2281_CR84","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1002\/cam4.1448","volume":"7","author":"CC Chen","year":"2018","unstructured":"Chen CC, Chang YT, Liu HN, Chen YJ. Cancer risk in patients with alopecia areata: a nationwide population-based matched cohort study. Cancer Med. 2018;7(5):2153\u20139. https:\/\/doi.org\/10.1002\/cam4.1448.","journal-title":"Cancer Med"},{"issue":"1","key":"2281_CR85","doi-asserted-by":"publisher","first-page":"9748","DOI":"10.1038\/s41598-018-28142-1","volume":"8","author":"JH Lee","year":"2018","unstructured":"Lee JH, Song Y, Do Han K, et al. Cancer risk by the subtype of alopecia. Sci Rep. 2018;8(1):9748. https:\/\/doi.org\/10.1038\/s41598-018-28142-1.","journal-title":"Sci Rep"},{"key":"2281_CR86","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.canep.2016.02.009","volume":"41","author":"A Mostaghimi","year":"2016","unstructured":"Mostaghimi A, Qureshi S, Joyce C, Guo Y, Huang KP. Reduced incidence of skin cancer in patients with alopecia areata: a retrospective cohort study. Cancer Epidemiol. 2016;41:129\u201331. https:\/\/doi.org\/10.1016\/j.canep.2016.02.009.","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"2281_CR87","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/BOR.0000000000000202","volume":"27","author":"GC Goobie","year":"2015","unstructured":"Goobie GC, Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol. 2015;27(5):454\u201360. https:\/\/doi.org\/10.1097\/BOR.0000000000000202.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"2281_CR88","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.semarthrit.2021.09.009","volume":"51","author":"AE Clarke","year":"2021","unstructured":"Clarke AE, Pooley N, Marjenberg Z, et al. Risk of malignancy in patients with systemic lupus erythematosus: systematic review and meta-analysis. Semin Arthritis Rheum. 2021;51(6):1230\u201341. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.09.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"2281_CR89","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/acr.21764","volume":"64","author":"JR Curtis","year":"2012","unstructured":"Curtis JR, Lanas A, John A, Johnson DA, Schulman KL. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(12):1819\u201328. https:\/\/doi.org\/10.1002\/acr.21764.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"2281_CR90","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"A Strangfeld","year":"2017","unstructured":"Strangfeld A, Richter A, Siegmund B, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504\u201310. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209773.","journal-title":"Ann Rheum Dis"},{"key":"2281_CR91","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022;81(3):33\u201343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2281_CR92","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206478.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2281_CR93","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.150613","volume":"43","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Emoto K, Cai Z, et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol. 2016;43(3):504\u201311. https:\/\/doi.org\/10.3899\/jrheum.150613.","journal-title":"J Rheumatol"},{"issue":"7","key":"2281_CR94","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1608345.","journal-title":"N Engl J Med"},{"issue":"13","key":"2281_CR95","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1507247.","journal-title":"N Engl J Med"},{"issue":"1","key":"2281_CR96","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210094.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2281_CR97","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506\u201317. https:\/\/doi.org\/10.1002\/art.39953.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"2281_CR98","first-page":"732","volume":"38","author":"Z Li","year":"2020","unstructured":"Li Z, Hu J, Bao C, et al. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase\u00a03 study. Clin Exp Rheumatol. 2020;38(4):732\u201341.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"2281_CR99","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385. https:\/\/doi.org\/10.1111\/jdv.16948.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2281_CR100","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242\u201355. https:\/\/doi.org\/10.1111\/bjd.18898.","journal-title":"Br J Dermatol"},{"key":"2281_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21630","author":"T Bieber","year":"2022","unstructured":"Bieber T, Reich K, Paul C, et al. BREEZE-AD4 study group. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance, or contraindication to cyclosporine: results from a randomized, placebo-controlled, Phase III Clinical Trial (BREEZE-AD4). Br J Dermatol. 2022. https:\/\/doi.org\/10.1111\/bjd.21630.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2281_CR102","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase\u00a03 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85(1):62\u201370. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.028.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2281_CR103","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260.","journal-title":"JAMA Dermatol"},{"key":"2281_CR104","first-page":"25","volume-title":"Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials (abstract)","author":"B King","year":"2022","unstructured":"King B, Mostaghimi A, Shimomura Y, et al. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials (abstract). Boston: American Academy of Dermatology Annual Meeting; 2022. p. 25\u20139."},{"issue":"4","key":"2281_CR105","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase\u00a02 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.050.","journal-title":"J Am Acad Dermatol"},{"key":"2281_CR106","unstructured":"King B, Ohyama M, Kwon O, et al. Efficacy and safety of baricitinib in adults with alopecia areata: phase\u00a03 results from two randomized controlled trials (BRAVE-AA1 and BRAVE-AA2) (poster). Presented at European Academy of Dermatology and Venereology Virtual Congress. 29 September\u20132 October 2021"},{"key":"2281_CR107","unstructured":"D\u00f6rner T, Tanaka Y, Mosca M, et al. Pooled safety analysis of baricitinib in patients with systemic lupus erythematosus: results from three randomised, double-blind, placebo-controlled, clinical trials (abstract 2375). Presented at EULAR 2022."},{"issue":"12","key":"2281_CR108","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC, Ramanan AV, de Bono S, et al. COV-BARRIER Study Group. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase\u00a03 trial. Lancet Respir Med. 2021;9(12):1407\u201318. https:\/\/doi.org\/10.1016\/S2213-2600(21)00331-3.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"2281_CR109","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al. ACTT-2 Study Group Members. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa2031994.","journal-title":"N Engl J Med"},{"issue":"4","key":"2281_CR110","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","volume":"10","author":"EW Ely","year":"2022","unstructured":"Ely EW, Ramanan AV, Kartman CE, et al. COV-BARRIER Study Group. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(4):327\u201336. https:\/\/doi.org\/10.1016\/S2213-2600(22)00006-6.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"2281_CR111","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","volume":"79","author":"KL Winthrop","year":"2020","unstructured":"Winthrop KL, Harigai M, Genovese MC, et al. Infections in baricitinib clinical trials for patients with active rheumatoid arthritis. Ann Rheum Dis. 2020;79(10):1290\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216852.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2281_CR112","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(7):1042\u201355. https:\/\/doi.org\/10.1002\/art.40841.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2281_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001370","volume":"6","author":"J Kay","year":"2020","unstructured":"Kay J, Harigai M, Rancourt J, et al. Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020;6(3): e001370. https:\/\/doi.org\/10.1136\/rmdopen-2020-001370.","journal-title":"RMD Open"},{"issue":"7","key":"2281_CR114","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","volume":"77","author":"PC Taylor","year":"2018","unstructured":"Taylor PC, Kremer JM, Emery P, et al. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018;77(7):988\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212461.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2281_CR115","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/1756-185X.13748","volume":"23","author":"YC Chen","year":"2020","unstructured":"Chen YC, Yoo DH, Lee CK, et al. Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: an integrated analysis from clinical trials. Int J Rheum Dis. 2020;23(1):65\u201373. https:\/\/doi.org\/10.1111\/1756-185X.13748.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"2281_CR116","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40257-021-00602-x","volume":"22","author":"B King","year":"2021","unstructured":"King B, Maari C, Lain E, et al. Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am J Clin Dermatol. 2021;22(3):395\u2013405. https:\/\/doi.org\/10.1007\/s40257-021-00602-x.","journal-title":"Am J Clin Dermatol"},{"key":"2281_CR117","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","volume":"400","author":"PW Horby","year":"2022","unstructured":"RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400(10349):359\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(22)01109-6.","journal-title":"Lancet"},{"key":"2281_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1744666X.2022.2014323","volume":"29","author":"MA Adas","year":"2021","unstructured":"Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol. 2021;29:1\u20139. https:\/\/doi.org\/10.1080\/1744666X.2022.2014323.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"2281_CR119","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","volume":"6","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3): e001395. https:\/\/doi.org\/10.1136\/rmdopen-2020-001395.","journal-title":"RMD Open"},{"issue":"3","key":"2281_CR120","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020;80(3):304\u201311. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510.","journal-title":"Ann Rheum Dis"},{"key":"2281_CR121","doi-asserted-by":"crossref","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase\u00a02 and phase\u00a03 clinical trial program. Presented at the AAD VMX 2021 Virtual Meeting Experience April 23\u201325, 2021b.","DOI":"10.1016\/j.jaad.2021.06.615"},{"key":"2281_CR122","unstructured":"European Medicine Agency. Assessment Report. Rinvoq. International non-proprietary name: upadacitinib. 24 June 2021. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/rinvoq-h-c-004760-x-0006-g-epar-assessment-report-variation_en.pdf. Accessed Apr 06, 2022."},{"issue":"9","key":"2281_CR123","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328\u201337. https:\/\/doi.org\/10.1002\/art.39670.","journal-title":"Arthritis Rheumatol"},{"issue":"10247","key":"2281_CR124","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(20)31286-1. Erratum in Lancet. 2020 Sep12;396(10253):758.","journal-title":"Lancet"},{"issue":"9","key":"2281_CR125","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46(9):2294\u2013300. https:\/\/doi.org\/10.1002\/art.10529.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2281_CR126","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","volume":"39","author":"DE Furst","year":"2010","unstructured":"Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39(5):327\u201346. https:\/\/doi.org\/10.1016\/j.semarthrit.2008.10.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"2281_CR127","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","volume":"76","author":"S Ramiro","year":"2017","unstructured":"Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101\u201336. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210708.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2281_CR128","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.autrev.2008.05.001","volume":"8","author":"R Caporali","year":"2008","unstructured":"Caporali R, Caprioli M, Bobbio-Pallavicini F, Montecucco C. DMARDS and infections in rheumatoid arthritis. Autoimmun Rev. 2008;8(2):139\u201343. https:\/\/doi.org\/10.1016\/j.autrev.2008.05.001.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2281_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-019-08768-3","volume":"59","author":"A Damour","year":"2020","unstructured":"Damour A, Garcia M, Seneschal J, L\u00e9v\u00eaque N, Bodet C. Eczema herpeticum: clinical and pathophysiological aspects. Clin Rev Allergy Immunol. 2020;59(1):1\u201318. https:\/\/doi.org\/10.1007\/s12016-019-08768-3.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2281_CR130","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jaci.2009.05.020","volume":"124","author":"LA Beck","year":"2009","unstructured":"Beck LA, Boguniewicz M, Hata T, et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol. 2009;124(2):260\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2009.05.020.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2281_CR131","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/jid.2008.259","volume":"129","author":"A De Benedetto","year":"2009","unstructured":"De Benedetto A, Agnihothri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol. 2009;129(1):14\u201330. https:\/\/doi.org\/10.1038\/jid.2008.259.","journal-title":"J Invest Dermatol"},{"key":"2281_CR132","first-page":"44","volume":"92","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatovener (Suppl). 1980;92:44\u20137.","journal-title":"Acta Dermatovener (Suppl)"},{"issue":"4","key":"2281_CR133","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaad.2018.11.028","volume":"80","author":"L Serrano","year":"2019","unstructured":"Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(4):904\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.028.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2281_CR134","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bjd.14708.C150","volume":"176","author":"MA Strom","year":"2017","unstructured":"Strom MA, Silverberg JI. Association between atopic dermatitis and extracutaneous infections in US adults. Br J Dermatol. 2017;176(2):495\u20137. https:\/\/doi.org\/10.1111\/bjd.14708.C150.","journal-title":"Br J Dermatol"},{"issue":"12","key":"2281_CR135","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1177\/0961203313493032","volume":"22","author":"A Danza","year":"2013","unstructured":"Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus. 2013;22(12):1286\u201394. https:\/\/doi.org\/10.1177\/0961203313493032.","journal-title":"Lupus"},{"issue":"5","key":"2281_CR136","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","volume":"82","author":"R Cervera","year":"2003","unstructured":"Cervera R, Khamashta MA, Font J, et al. European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299\u2013308. https:\/\/doi.org\/10.1097\/01.md.0000091181.93122.55.","journal-title":"Medicine (Baltimore)"},{"key":"2281_CR137","unstructured":"Fujii T, Atsumi T, Okamoto N, et al. Safety of baricitinib in Japanese patients with rheumatoid arthritis (RA): The 2020 interim report from all-case post marketing surveillance in clinical practice [abstract 1676]. Arthritis Rheumatol. 2021; 73 (suppl 10). https:\/\/acrabstracts.org\/abstract\/safety-of-baricitinib-in-japanese-patients-with-rheumatoid-arthritis-ra-the-2020-interim-report-from-all-case-post-marketing-surveillance-in-clinical-practice\/. Accessed Jan 31, 2022."},{"issue":"10","key":"2281_CR138","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66(10):2675\u201384. https:\/\/doi.org\/10.1002\/art.38745.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"2281_CR139","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jaci.2011.02.010","volume":"127","author":"DY Leung","year":"2011","unstructured":"Leung DY, Gao PS, Grigoryev DN, et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-\u03b3 response. J Allergy Clin Immunol. 2011;127(4):965\u201373. https:\/\/doi.org\/10.1016\/j.jaci.2011.02.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2281_CR140","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/jdv.16090","volume":"34","author":"M Seegr\u00e4ber","year":"2020","unstructured":"Seegr\u00e4ber M, Worm M, Werfel T, et al. Recurrent eczema herpeticum\u2014a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2020;34(5):1074\u20139. https:\/\/doi.org\/10.1111\/jdv.16090.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2281_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-018-8714-z","volume":"58","author":"F Carbone","year":"2020","unstructured":"Carbone F, Bonaventura A, Liberale L, et al. Atherosclerosis in rheumatoid arthritis: promoters and opponents. Clin Rev Allergy Immunol. 2020;58(1):1\u201314. https:\/\/doi.org\/10.1007\/s12016-018-8714-z.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"2281_CR142","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/nrrheum.2015.40.1","volume":"11","author":"S Skeoch","year":"2015","unstructured":"Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 2015;11(7):390\u2013400. https:\/\/doi.org\/10.1038\/nrrheum.2015.40.1.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"2281_CR143","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1002\/art.30542","volume":"63","author":"JT Giles","year":"2011","unstructured":"Giles JT, Post WS, Blumenthal RS, et al. Longitudinal predictors of progression of carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2011;63(11):3216\u201325. https:\/\/doi.org\/10.1002\/art.30542.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2281_CR144","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/ar3382","volume":"13","author":"C Gonz\u00e1lez-Juanatey","year":"2011","unstructured":"Gonz\u00e1lez-Juanatey C, Llorca J, Gonz\u00e1lez-Gay MA. Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther. 2011;13(3):R101. https:\/\/doi.org\/10.1186\/ar3382.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2281_CR145","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/ard.2008.101964","volume":"68","author":"E Choy","year":"2009","unstructured":"Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68(4):460\u20139. https:\/\/doi.org\/10.1136\/ard.2008.101964.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2281_CR146","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206624.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2281_CR147","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","volume":"72","author":"S Singh","year":"2020","unstructured":"Singh S, Fumery M, Singh AG, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020;72(4):561\u201376. https:\/\/doi.org\/10.1002\/acr.23875.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"2281_CR148","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011870","volume":"6","author":"J Lindorff Riis","year":"2016","unstructured":"Lindorff Riis J, Vestergaard C, Hjuler KF, et al. Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study. BMJ Open. 2016;6(11): e011870. https:\/\/doi.org\/10.1136\/bmjopen-2016-011870.","journal-title":"BMJ Open"},{"issue":"361","key":"2281_CR149","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1786","volume":"23","author":"RJ Silverwood","year":"2018","unstructured":"Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018;23(361): k1786. https:\/\/doi.org\/10.1136\/bmj.k1786.","journal-title":"BMJ"},{"issue":"5","key":"2281_CR150","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jid.2016.11.031","volume":"137","author":"M Standl","year":"2017","unstructured":"Standl M, Tesch F, Baurecht H, et al. Association of atopic dermatitis with cardiovascular risk factors and diseases. J Invest Dermatol. 2017;137(5):1074\u201381. https:\/\/doi.org\/10.1016\/j.jid.2016.11.031.","journal-title":"J Invest Dermatol"},{"issue":"49","key":"2281_CR151","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013512","volume":"97","author":"M Yuan","year":"2018","unstructured":"Yuan M, Cao WF, Xie XF, Zhou HY, Wu XM. Relationship of atopic dermatitis with stroke and myocardial infarction: a meta-analysis. Medicine (Baltimore). 2018;97(49): e13512. https:\/\/doi.org\/10.1097\/MD.0000000000013512.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2281_CR152","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.16939","volume":"179","author":"JP Thyssen","year":"2018","unstructured":"Thyssen JP, Egeberg A. Cardiovascular disease and atopic dermatitis: epidemiological strengths and limitations. Br J Dermatol. 2018;179(4):1014\u20135. https:\/\/doi.org\/10.1111\/bjd.16939.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2281_CR153","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bjd.20661","volume":"186","author":"M Yousaf","year":"2022","unstructured":"Yousaf M, Ayasse M, Ahmed A, et al. Association between atopic dermatitis and hypertension: a systematic review and meta-analysis. Br J Dermatol. 2022;186(2):227\u201335. https:\/\/doi.org\/10.1111\/bjd.20661.","journal-title":"Br J Dermatol"},{"issue":"10","key":"2281_CR154","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1111\/all.14859","volume":"76","author":"AP Villani","year":"2021","unstructured":"Villani AP, Pavel AB, Wu J, et al. Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. Allergy. 2021;76(10):3107\u201321. https:\/\/doi.org\/10.1111\/all.14859.","journal-title":"Allergy"},{"issue":"9","key":"2281_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.810092","volume":"21","author":"Z Tang","year":"2022","unstructured":"Tang Z, Shen M, Xiao Y, Liu H, Chen X. Association between atopic dermatitis, asthma, and serum lipids: a UK biobank based observational study and mendelian randomization analysis. Front Med (Lausanne). 2022;21(9): 810092. https:\/\/doi.org\/10.3389\/fmed.2022.810092.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"2281_CR156","doi-asserted-by":"publisher","first-page":"11718","DOI":"10.1038\/srep11718","volume":"26","author":"JH Kang","year":"2015","unstructured":"Kang JH, Lin HC, Kao S, Tsai MC, Chung SD. Alopecia areata increases the risk of stroke: a 3-year follow-up study. Sci Rep. 2015;26(5):11718. https:\/\/doi.org\/10.1038\/srep11718.","journal-title":"Sci Rep"},{"key":"2281_CR157","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-med-060911-090007","volume":"64","author":"JM Kahlenberg","year":"2013","unstructured":"Kahlenberg JM, Kaplan MJ. Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. Annu Rev Med. 2013;64:249\u201363. https:\/\/doi.org\/10.1146\/annurev-med-060911-090007.","journal-title":"Annu Rev Med"},{"issue":"1","key":"2281_CR158","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/0961203316651739","volume":"26","author":"J HalskouHesselvig","year":"2017","unstructured":"HalskouHesselvig J, Ahlehoff O, Dreyer L, Gislason G, Kofoed K. Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. Lupus. 2017;26(1):48\u201353. https:\/\/doi.org\/10.1177\/0961203316651739.","journal-title":"Lupus"},{"issue":"3","key":"2281_CR159","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.tcm.2020.12.004","volume":"31","author":"MAM Ali","year":"2021","unstructured":"Ali MAM, Spinler SA. COVID-19 and thrombosis: from bench to bedside. Trends Cardiovasc Med. 2021;31(3):143\u201360. https:\/\/doi.org\/10.1016\/j.tcm.2020.12.004.","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"2281_CR160","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles JT, Sattar N, Gabriel S, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72(1):31\u201340. https:\/\/doi.org\/10.1002\/art.41095.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2281_CR161","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78(8):1048\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214846.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2281_CR162","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","volume":"37","author":"K Kume","year":"2017","unstructured":"Kume K, Amano K, Yamada S, et al. Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatol Int. 2017;37(12):2079\u201385. https:\/\/doi.org\/10.1007\/s00296-017-3844-9.","journal-title":"Rheumatol Int"},{"issue":"2","key":"2281_CR163","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbrc.2017.06.020","volume":"490","author":"Z Wang","year":"2017","unstructured":"Wang Z, Wang S, Wang Z, Yun T, Wang C, Wang H. Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice. Biochem Biophys Res Commun. 2017;490(2):194\u2013201. https:\/\/doi.org\/10.1016\/j.bbrc.2017.06.020.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2281_CR164","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA, et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum. 2016;46(3):261\u201371. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.014.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"2281_CR165","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"key":"2281_CR166","unstructured":"Pfizer Laboratories Div Pfizer Inc. XELJANZ- tofacitinib. December 2021. https:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959. Accessed Feb 24, 2022."},{"key":"2281_CR167","unstructured":"U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Approved uses also being limited to certain patients. December 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed Feb 25, 2022."},{"key":"2281_CR168","unstructured":"Pfizer Europe MA EEIG. Xeljanz. Tofacitinib: Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf. Accessed Feb 25, 2022"},{"key":"2281_CR169","doi-asserted-by":"publisher","first-page":"annrheumdis-202","DOI":"10.1136\/annrheumdis-2021-221915","volume":"13","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;13:annrheumdis-2021-221915. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221915.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2281_CR170","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.105122","volume":"88","author":"C Ketfi","year":"2021","unstructured":"Ketfi C, Boutigny A, Mohamedi N, et al. Risk of venous thromboembolism in rheumatoid arthritis. Joint Bone Spine. 2021;88(3): 105122. https:\/\/doi.org\/10.1016\/j.jbspin.2020.105122.","journal-title":"Joint Bone Spine"},{"issue":"5","key":"2281_CR171","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13075-014-0435-y","volume":"16","author":"JJ Lee","year":"2014","unstructured":"Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435. https:\/\/doi.org\/10.1186\/s13075-014-0435-y.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2281_CR172","doi-asserted-by":"publisher","first-page":"539.e7","DOI":"10.1016\/j.amjmed.2014.11.025","volume":"128","author":"SC Kim","year":"2015","unstructured":"Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015;128(5):539.e7-17. https:\/\/doi.org\/10.1016\/j.amjmed.2014.11.025.","journal-title":"Am J Med"},{"issue":"2","key":"2281_CR173","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001013","volume":"5","author":"H Liang","year":"2019","unstructured":"Liang H, Danwada R, Guo D, et al. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. RMD Open. 2019;5(2): e001013. https:\/\/doi.org\/10.1136\/rmdopen-2019-001013.","journal-title":"RMD Open"},{"issue":"4","key":"2281_CR174","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/rheumatology\/keu408","volume":"54","author":"P Ungprasert","year":"2015","unstructured":"Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL. Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis. Rheumatology (Oxford). 2015;54(4):736\u201342. https:\/\/doi.org\/10.1093\/rheumatology\/keu408.","journal-title":"Rheumatology (Oxford)"},{"key":"2281_CR175","doi-asserted-by":"crossref","unstructured":"Desai PV, Akhtar T, Patel A, et al. Abstract 12499: risk of venous thromboembolism in autoimmune connective tissue diseases: a population-based retrospective study. Circulation. 2021;144(Suppl 1).","DOI":"10.1161\/circ.144.suppl_1.12499"},{"issue":"4","key":"2281_CR176","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/jth.12518","volume":"12","author":"WS Chung","year":"2014","unstructured":"Chung WS, Lin CL, Chang SN, Lu CC, Kao CH. Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. J Thromb Haemost. 2014;12(4):452\u20138. https:\/\/doi.org\/10.1111\/jth.12518.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2281_CR177","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1538-7836.2012.04666.x","volume":"10","author":"SA Johannesdottir","year":"2012","unstructured":"Johannesdottir SA, Schmidt M, Horv\u00e1th-Puh\u00f3 E, S\u00f8rensen HT. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost. 2012;10(5):815\u201321. https:\/\/doi.org\/10.1111\/j.1538-7836.2012.04666.x.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2281_CR178","first-page":"171","volume":"2","author":"B Z\u00f6ller","year":"2012","unstructured":"Z\u00f6ller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis. 2012;2(3):171\u201383.","journal-title":"Am J Cardiovasc Dis"},{"issue":"3","key":"2281_CR179","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2020.100742","volume":"46","author":"JE G\u00f3mez-Mesa","year":"2021","unstructured":"G\u00f3mez-Mesa JE, Galindo-Coral S, Montes MC, Mu\u00f1oz Martin AJ. Thrombosis and cagulopathy in COVID-19. Curr Probl Cardiol. 2021;46(3): 100742. https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100742.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"2281_CR180","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10456-020-09753-7","volume":"24","author":"A Rovas","year":"2021","unstructured":"Rovas A, Osiaevi I, Buscher K, et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2021;24(1):145\u201357. https:\/\/doi.org\/10.1007\/s10456-020-09753-7.","journal-title":"Angiogenesis"},{"issue":"1","key":"2281_CR181","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jaci.2020.08.031","volume":"147","author":"JT Sims","year":"2021","unstructured":"Sims JT, Krishnan V, Chang CY, et al. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol. 2021;147(1):107\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2020.08.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"2281_CR182","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/VHRM.S299357","volume":"1","author":"JC Chang","year":"2021","unstructured":"Chang JC. COVID-19 sepsis: pathogenesis and endothelial molecular mechanisms based on \u201ctwo-path unifying theory\u201d of hemostasis and endotheliopathy-associated vascular microthrombotic disease, and proposed therapeutic approach with antimicrothrombotic therapy. Vasc Health Risk Manag. 2021;1(17):273\u201398. https:\/\/doi.org\/10.2147\/VHRM.S299357.","journal-title":"Vasc Health Risk Manag"},{"issue":"Suppl 1","key":"2281_CR183","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/ijlh.12830","volume":"40","author":"M Levi","year":"2018","unstructured":"Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. Int J Lab Hematol. 2018;40(Suppl 1):15\u201320. https:\/\/doi.org\/10.1111\/ijlh.12830.","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"2281_CR184","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","volume":"18","author":"N Tang","year":"2020","unstructured":"Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844\u20137. https:\/\/doi.org\/10.1111\/jth.14768.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2281_CR185","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","volume":"12","author":"JA Heit","year":"2015","unstructured":"Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464\u201374. https:\/\/doi.org\/10.1038\/nrcardio.2015.83.","journal-title":"Nat Rev Cardiol"},{"issue":"23 Suppl 1","key":"2281_CR186","doi-asserted-by":"publisher","first-page":"I4","DOI":"10.1161\/01.CIR.0000078468.11849.66","volume":"107","author":"RH White","year":"2003","unstructured":"White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I4-8. https:\/\/doi.org\/10.1161\/01.CIR.0000078468.11849.66.","journal-title":"Circulation"},{"issue":"11","key":"2281_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102658","volume":"19","author":"Z Szekanecz","year":"2020","unstructured":"Szekanecz Z, Gomez I, So\u00f3s B, et al. Hungarian OncoRheumatology Network (HORN) initiative. Eight pillars of oncorheumatology: crossroads between malignancies and musculoskeletal diseases. Autoimmun Rev. 2020;19(11): 102658. https:\/\/doi.org\/10.1016\/j.autrev.2020.102658.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2281_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2017.1352477","volume":"28","author":"M Harigai","year":"2018","unstructured":"Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective. Mod Rheumatol. 2018;28(1):1\u20138. https:\/\/doi.org\/10.1080\/14397595.2017.1352477.","journal-title":"Mod Rheumatol"},{"issue":"11","key":"2281_CR189","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","volume":"177","author":"H Wadstr\u00f6m","year":"2017","unstructured":"Wadstr\u00f6m H, Frisell T, Askling J. Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 2017;177(11):1605\u201312. https:\/\/doi.org\/10.1001\/jamainternmed.2017.4332.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"2281_CR190","first-page":"2130","volume":"32","author":"EF Chakravarty","year":"2005","unstructured":"Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol. 2005;32(11):2130\u20135.","journal-title":"J Rheumatol"},{"issue":"6","key":"2281_CR191","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.38385","volume":"66","author":"RL Gross","year":"2014","unstructured":"Gross RL, Schwartzman-Morris JS, Krathen M, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014;66(6):1472\u201381. https:\/\/doi.org\/10.1002\/art.38385.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2281_CR192","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208105","volume":"75","author":"J Askling","year":"2016","unstructured":"Askling J, Berglind N, Franzen S, et al. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Ann Rheum Dis. 2016;75(10):1789\u201396. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208105.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2281_CR193","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","volume":"156","author":"KE Mansfield","year":"2020","unstructured":"Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086\u201397. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1948.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2281_CR194","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1365-2133.2010.09887.x","volume":"163","author":"A Arana","year":"2010","unstructured":"Arana A, Wentworth CE, Fern\u00e1ndez-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the UK. Br J Dermatol. 2010;163(5):1036\u201343. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09887.x (Erratum in Br J Dermatol. 2011 Jan;164(1):230).","journal-title":"Br J Dermatol"},{"issue":"1","key":"2281_CR195","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000213","volume":"2","author":"A Rubbert-Roth","year":"2016","unstructured":"Rubbert-Roth A, Sebba A, Brockwell L, et al. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD Open. 2016;2(1):e000213. https:\/\/doi.org\/10.1136\/rmdopen-2015-000213.","journal-title":"RMD Open"},{"issue":"10","key":"2281_CR196","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2020.2240","volume":"156","author":"MM Asgari","year":"2020","unstructured":"Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatol. 2020;156(10):1066\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2020.2240.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2281_CR197","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1365-2133.2005.07077.x","volume":"154","author":"H Wang","year":"2006","unstructured":"Wang H, Diepgen TL. Atopic dermatitis and cancer risk. Br J Dermatol. 2006;154(2):205\u201310. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.07077.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2281_CR198","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1001\/jamadermatol.2019.3786","volume":"156","author":"L Wang","year":"2020","unstructured":"Wang L, Bierbrier R, Drucker AM, Chan AW. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(2):158\u201371. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3786.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2281_CR199","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","volume":"72","author":"L Legendre","year":"2015","unstructured":"Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;72(6):992\u20131002. https:\/\/doi.org\/10.1016\/j.jaad.2015.02.1116.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2281_CR200","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/11593280-000000000-00000","volume":"13","author":"AO Jensen","year":"2012","unstructured":"Jensen AO, Svaerke C, K\u00f6rmendin\u00e9 Farkas D, Olesen AB, Kragballe K, S\u00f8rensen HT. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977\u20132006). Am J Clin Dermatol. 2012;13(1):29\u201336. https:\/\/doi.org\/10.2165\/11593280-000000000-00000.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"2281_CR201","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jdermsci.2016.07.009","volume":"84","author":"S Gandini","year":"2016","unstructured":"Gandini S, Stanganelli I, Palli D, De Giorgi V, Masala G, Caini S. Atopic dermatitis, naevi count and skin cancer risk: a meta-analysis. J Dermatol Sci. 2016;84(2):137\u201343. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.07.009.","journal-title":"J Dermatol Sci"},{"issue":"11","key":"2281_CR202","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","volume":"49","author":"S Reuter","year":"2010","unstructured":"Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603\u201316. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2010.09.006.","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"2281_CR203","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.berh.2017.09.013","volume":"31","author":"MY Choi","year":"2017","unstructured":"Choi MY, Flood K, Bernatsky S, Ramsey-Goldman R, Clarke AE. A review on SLE and malignancy. Best Pract Res Clin Rheumatol. 2017;31(3):373\u201396. https:\/\/doi.org\/10.1016\/j.berh.2017.09.013.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"157","key":"2281_CR204","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004385","volume":"4","author":"JE Hansen","year":"2012","unstructured":"Hansen JE, Chan G, Liu Y, et al. Targeting cancer with a lupus autoantibody. Sci Transl Med. 2012;4(157): 157ra142. https:\/\/doi.org\/10.1126\/scitranslmed.3004385.","journal-title":"Sci Transl Med"},{"issue":"8","key":"2281_CR205","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3899\/jrheum.201183","volume":"48","author":"A Kavanaugh","year":"2021","unstructured":"Kavanaugh A, Westhovens RR, Winthrop KL, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. J Rheumatol. 2021;48(8):1230\u20138. https:\/\/doi.org\/10.3899\/jrheum.201183.","journal-title":"J Rheumatol"},{"issue":"2","key":"2281_CR206","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","volume":"49","author":"SC Kim","year":"2019","unstructured":"Kim SC, Pawar A, Desai RJ, et al. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study. Semin Arthritis Rheum. 2019;49(2):222\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.03.002.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"2281_CR207","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s10067-011-1827-x","volume":"30","author":"T Gout","year":"2011","unstructured":"Gout T, Ost\u00f6r AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol. 2011;30(11):1471\u20134. https:\/\/doi.org\/10.1007\/s10067-011-1827-x.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"2281_CR208","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/bjs.6226","volume":"95","author":"CR Morris","year":"2008","unstructured":"Morris CR, Harvey IM, Stebbings WS, Hart AR. Incidence of perforated diverticulitis and risk factors for death in a UK population. Br J Surg. 2008;95(7):876\u201381. https:\/\/doi.org\/10.1002\/bjs.6226.","journal-title":"Br J Surg"},{"issue":"1","key":"2281_CR209","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12865-020-00365-w","volume":"21","author":"Y Fujita","year":"2020","unstructured":"Fujita Y, Matsuoka N, Temmoku J, et al. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells. BMC Immunol. 2020;21(1):35. https:\/\/doi.org\/10.1186\/s12865-020-00365-w.","journal-title":"BMC Immunol"},{"issue":"9","key":"2281_CR210","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood.v98.9.2720","volume":"98","author":"A Kaser","year":"2001","unstructured":"Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720\u20135. https:\/\/doi.org\/10.1182\/blood.v98.9.2720.","journal-title":"Blood"},{"issue":"8","key":"2281_CR211","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fendo.2017.00059","volume":"31","author":"LN Varghese","year":"2017","unstructured":"Varghese LN, Defour JP, Pecquet C, Constantinescu SN. The thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin. Front Endocrinol (Lausanne). 2017;31(8):59. https:\/\/doi.org\/10.3389\/fendo.2017.00059.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2281_CR212","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25\u201336. https:\/\/doi.org\/10.1038\/nrrheum.2015.167.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2281_CR213","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1136\/ard.55.3.162","volume":"55","author":"HR Peeters","year":"1996","unstructured":"Peeters HR, Jongen-Lavrencic M, Raja AN, et al. Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset. Ann Rheum Dis. 1996;55(3):162\u20138. https:\/\/doi.org\/10.1136\/ard.55.3.162.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2281_CR214","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00541320","volume":"9","author":"G Vreugdenhil","year":"1990","unstructured":"Vreugdenhil G, Swaak AJ. Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment. Rheumatol Int. 1990;9(6):243\u201357. https:\/\/doi.org\/10.1007\/BF00541320.","journal-title":"Rheumatol Int"},{"issue":"1","key":"2281_CR215","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3899\/jrheum.090168","volume":"37","author":"FK Chan","year":"2010","unstructured":"Chan FK, Cryer B, Goldstein JL, et al. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol. 2010;37(1):167\u201374. https:\/\/doi.org\/10.3899\/jrheum.090168.","journal-title":"J Rheumatol"},{"issue":"4","key":"2281_CR216","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jbspin.2015.01.005","volume":"82","author":"E Lazaro","year":"2015","unstructured":"Lazaro E, Morel J. Management of neutropenia in patients with rheumatoid arthritis. Joint Bone Spine. 2015;82(4):235\u20139. https:\/\/doi.org\/10.1016\/j.jbspin.2015.01.005.","journal-title":"Joint Bone Spine"},{"key":"2281_CR217","unstructured":"Giles JT, Nurmohamed MT, Rinder HM, et al. Mean platelet volume changes with baricitinib indicate reduced new platelet production in baricitinib-treated rheumatoid arthritis patients [abstract]. Arthritis Rheumatol. 2018; 70(suppl 10). https:\/\/acrabstracts.org\/abstract\/mean-platelet-volume-changes-with-baricitinib-indicate-reduced-new-platelet-production-in-baricitinib-treated-rheumatoid-arthritis-patients\/. Accessed Apr 7, 2022."},{"issue":"2019","key":"2281_CR218","doi-asserted-by":"publisher","first-page":"9213074","DOI":"10.1155\/2019\/9213074","volume":"17","author":"A Korniluk","year":"2019","unstructured":"Korniluk A, Koper-Lenkiewicz OM, Kami\u0144ska J, Kemona H, Dymicka-Piekarska V. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm. 2019;17(2019):9213074. https:\/\/doi.org\/10.1155\/2019\/9213074.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"2281_CR219","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1538-7836.2009.03498.x","volume":"8","author":"SK Braekkan","year":"2010","unstructured":"Braekkan SK, Mathiesen EB, Nj\u00f8lstad I, Wilsgaard T, St\u00f8rmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Troms\u00f8 Study, Troms\u00f8, Norway. J Thromb Haemost. 2010;8(1):157\u201362. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03498.x.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2281_CR220","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/annrheumdis-2013-203293","volume":"73","author":"H Johnsson","year":"2014","unstructured":"Johnsson H, Panarelli M, Cameron A, Sattar N. Analysis and modelling of cholesterol and high-density lipoprotein cholesterol changes across the range of C-reactive protein levels in clinical practice as an aid to better understanding of inflammation-lipid interactions. Ann Rheum Dis. 2014;73(8):1495\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203293.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2281_CR221","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000511759","volume":"144","author":"A Klein","year":"2021","unstructured":"Klein A, Molad Y. Hematological manifestations among patients with rheumatic diseases. Acta Haematol. 2021;144(4):403\u201312. https:\/\/doi.org\/10.1159\/000511759.","journal-title":"Acta Haematol"},{"issue":"5","key":"2281_CR222","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.semarthrit.2015.10.010","volume":"45","author":"K Tselios","year":"2016","unstructured":"Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum. 2016;45(5):604\u201310. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.10.010.","journal-title":"Semin Arthritis Rheum"}],"updated-by":[{"DOI":"10.1007\/s12325-023-02526-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02281-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02281-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T07:04:08Z","timestamp":1727939048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02281-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":222,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["2281"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02281-4","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-023-02526-w","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"7 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-023-02526-w","URL":"https:\/\/doi.org\/10.1007\/s12325-023-02526-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}